Dishman Carbogen Amcis Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/v60y1fmdw87tevw9r33ctfy3.pdf

Key Takeaways


Demand Environment & Market Recovery

Villemagne: "Now they know, so now they act. That's so it for CRAMs. We have seen very quickly some things starting to change from last week. Nothing concrete yet, of course. It's a bit new, but we have been seeing that now the election is done, that's going to really move forward and especially from a venture capital perspectives, reinforce some of our customers that they were looking for an additional table to come out."

Segment Performance

SegmentTrendCommentary
Carbogen Amcis▲ ImprovingQ1 was weak, but Q2 was better, driven by high commercial product revenue and a CHF0.98 crore shipment spillover from Q1; on track to match the ~CHF25.5 crore budget for the year.
India CRAMS▲ Strong growthRevenue grew 37% on the back of regulatory clearances received, leading to an increased order book from existing and potentially new customers.
Cholesterol & Vitamin D▼ Revenue, ▲ MarginRevenue declined YoY due to lower cholesterol asset sales and a post-COVID slowdown in vitamin D consumption, but margin improved to 14.7% from 10% due to a better product mix.
India Quats & Generics▼ SoftRevenue declined due to an agrochemical industry slowdown; a pickup is expected from the beginning of the new calendar year, with full-year revenue of INR80-90 crores at 6-7% margins.
French Facility▬ RampingChallenges are resolved and the facility is fully validated, but not yet running at full capacity; H2 revenue is expected at ~€0.6 crore with an EBITDA loss of ~€0.15 crore.

Margins: The Recovery Path

Dalal: "So that is the goal for the next 2 years to 3 years, that is where we want to get at, and then we could move towards the 30% margin."

Pipeline & Portfolio Dynamics

Villemagne: "In my 25 years of experience in that industry, it's very often the marketing figures that was provided. We are not totally right. So there was always either a overestimation, very often an overestimation. And sometimes, yes, an underestimation. But it's almost an impossible to predict, which molecule is going to happen."

Operational & Strategic Updates

Villemagne: "And we are engaging new discussion with that specific customer to further invest in another facility to debottleneck the supply chain for the future as well and we are speaking about a 2-digit million investment in that particular facility."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue growthAt least 8% to 9%FY25
Full-year consolidated EBITDA marginAt least 16% to 17%FY25
Carbogen Amcis revenueMatch budget target of ~CHF 25.5 croreFY25
Bavla site revenue~INR 300 crores (revised from INR 350 crores)FY25
Bavla site growth25% to 30% growthFY26
Net debt reductionDecrease to CHF 15-16 crore from CHF 17.3 croreBy March '25
Net debt-to-EBITDA ratioBelow 2xNext 2 to 2.5 financial years
Net debt-to-EBITDA ratioBetween 1.5x to 2xBy FY27
Consolidated EBITDA marginReach 25%, then move toward 30%Next 2 to 3 years
French facility EBITDA lossNarrow to ~€0.15 croreH2 FY25
India Quats & Generics pickupRecovery to beginBeginning of new calendar year
Wool grease price benefitReduced raw material costs to accrueFrom January (Q4 FY25)
SAP operational go-liveNew fiscal year '25From April 1st

Key Metrics

MetricQ2 FY25
Revenue₹789 cr, +35% YoY from ₹586 cr in Q2 FY24
Cost of goods sold~24% of revenue, vs historical average of ~20% due to higher commercial revenue share
Employee expenses~₹320 cr, in line with Q1 FY25
Other expenses~₹130 cr, including notional FX loss
EBITDA₹148 cr, one of the highest in company history
Profit before tax₹42 cr
Tax expense~₹9 cr, ~20-22% of PBT
PAT₹33 cr, PAT margin of 4.2%
Full-year revenue growth guidanceAt least 8% to 9%
Full-year consolidated EBITDA margin guidanceAt least 16%
Carbogen Amcis CRAMS revenue₹663 cr, +52% YoY from ₹437 cr in Q2 FY24
Carbogen Amcis CRAMS EBITDA margin~20%, vs 12.2% in Q2 FY24
Cholesterol and Vitamin D analogues revenue₹55 cr, vs ₹86 cr in Q2 FY24
Cholesterol and Vitamin D analogues EBITDA margin14.7%, vs 10% in Q2 FY24
India CRAMS revenue₹49 cr, +37% YoY from ₹36 cr in Q2 FY24
India CRAMS EBITDA margin~14%
India Quats and Generic revenue₹21 cr, vs ₹27 cr in Q2 FY24
India Quats and Generic EBITDA margin~7%
Net debtCHF 17.3 cr as of 30 Sep, vs CHF 16.2 cr as of Mar FY24
Net debt expected as of March FY25CHF 15 cr to CHF 16 cr
Net debt-to-EBITDA target1.5 to 2 by FY27
Total CapEx H1 FY25~₹125 cr; full year expected ~₹250 cr
Carbogen Amcis order book~CHF 11 cr as of 30 Sep, down from CHF 14.2 cr
Carbogen Amcis FY25 budget targetCHF 25.5 cr
French facility H1 FY25 revenue€0.35 cr; EBITDA loss of €0.4 cr
French facility H2 FY25 expected revenue€0.6 cr; expected EBITDA loss of €0.15 cr
Bavla site FY25 revenue expectedCloser to ~₹300 cr, vs earlier guidance of ₹350 cr
Bavla site next FY growth expectation25% to 30%
Quats and Generics FY25 revenue expected~₹80 cr to ₹90 cr
Revenue spillover from Q1 to Q2CHF 0.98 cr
Long-term EBITDA margin target25% over next 2-3 years, eventually moving towards 30%